

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 39/02, 39/00, A01N 63/00		A1	(11) International Publication Number: WO 00/09156 (43) International Publication Date: 24 February 2000 (24.02.00)
(21) International Application Number: PCT/US99/18197 (22) International Filing Date: 11 August 1999 (11.08.99) (30) Priority Data: 09/133,089 12 August 1998 (12.08.98) US (71) Applicant (for all designated States except US): LOMA LINDA UNIVERSITY [US/US]; Loma Linda, CA 92350 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): FLETCHER, Hansel, M. [US/US]; 25927 Brookmere Avenue, Loma Linda, CA 92354 (US). (74) Agents: FARAH, David, A. et al.; Sheldon & Mak, 9th floor, 225 South Lake Avenue, Pasadena, CA 91101 (US).			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published With international search report. With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.
(54) Title: NON-VIRULENT <i>PORPHYROMONAS GINGIVALIS</i> MUTANT			
(57) Abstract  A non-virulent, <i>recA</i> defective mutant of <i>Porphyromonas gingivalis</i> . The <i>Porphyromonas gingivalis</i> strain which is deposited at ATCC under accession number 202109. Also a method of decreasing the growth rate or reproduction rate of <i>Porphyromonas gingivalis</i> in a mammal comprising the step of administering to the mammal at least one dose of <i>Porphyromonas gingivalis</i> according to the present invention. Further, a method of preventing or treating a <i>Porphyromonas gingivalis</i> infection such as periodontitis in a mammal comprising the step of administering to the mammal at least one dose of <i>Porphyromonas gingivalis</i> according to the present invention. Also, a pharmaceutical composition comprising a non-virulent, <i>recA</i> defective mutant of <i>Porphyromonas gingivalis</i> .			

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## NON-VIRULENT *PORPHYROMONAS GINGIVALIS* MUTANT

### BACKGROUND

Periodontitis is an inflammatory disease of the tissues surrounding the teeth characterized by loss of the periodontal ligament attachment and alveolar bone support of the tooth. Periodontitis affects more than 49 million people in the United States and hundreds of millions of people worldwide and has been reported as a risk factor for cardiovascular disease and pre-term delivery of low-birth-weight infants. The most common cause of periodontitis is chronic Gram-negative bacterial infections. Among the Gram-negative bacteria implicated as a cause of periodontitis, *Porphyromonas gingivalis* is the major component of the flora in over 90% of adult periodontitis lesions.

Besides being a major etiological agent in adult human periodontitis, *Porphyromonas gingivalis* also causes aspiration pneumonia and necrotizing pneumonia, abscesses in brain, genitourinary tract and lung, as well as mediastinitis. By contrast, *P. gingivalis* is not normally found at healthy sites nor is it found in patients with gingivitis but with no accompanying periodontitis.

The current therapy for periodontitis is directed toward identifying, removing and controlling the etiologic factors, and then correcting the defects these pathogens have caused. These therapies include scaling and root planing, chemotherapy, periodontal surgery and periodic maintenance therapy. However, these treatments are not entirely effective because, for example, the pathogens can become resistant to chemotherapeutic agents.

Several potential virulence factors have been identified which appear to relate to the pathogenicity of *P. gingivalis* in periodontitis. These factors include fimbriae (adhesins), capsule (antiphagocytosis), lipopolysaccharide (bone resorption), proteases (specific and generalized tissue destruction) and a variety of toxic by-products (e.g., ammonia). Some of these factors have been purified and biochemically characterized. However, the specific roles, interactions, relative importance and regulation of these factors remains to be determined.

Therefore, there remains a need for effective prevention and treatment for periodontitis. Further, there remains a need for a modified strain of *P. gingivalis* that can be used as a host genetic background to determine the specific roles, interactions, relative

importance and regulation of the potential virulence factors produced by wild-type *P. gingivalis*.

### SUMMARY

According to one embodiment of the present invention, there is provided a  
5 non-virulent, *recA* defective mutant of *Porphyromonas gingivalis*. According to another  
embodiment of the present invention, there is provided a *Porphyromonas gingivalis* strain  
which is deposited at ATCC under accession number 202109.

According to another embodiment of the present invention, there is provided  
a pharmaceutical preparation comprising a mutant of *Porphyromonas gingivalis* according to  
10 the present invention.

According to another embodiment of the present invention, there is provided a  
method of decreasing the growth rate or reproduction rate of *Porphyromonas gingivalis* in a  
mammal, such as a human. The method comprises the step of administering to the mammal  
at least one dose of a non-virulent, *recA* defective mutant of *Porphyromonas gingivalis*, such  
15 as at least one dose of a *Porphyromonas gingivalis* strain which is deposited at ATCC under  
accession number 202109.

According to another embodiment of the present invention, there is provided a  
method of preventing or treating a *Porphyromonas gingivalis* infection such as periodontitis  
in a mammal, such as a human. The method comprises the step of administering to the  
20 mammal at least one dose of *Porphyromonas gingivalis* according to the present invention.

The methods of the present invention can be performed by administering to the  
mutant with the at least one dose of a non-virulent, *recA* defective mutant of *Porphyromonas*  
*gingivalis* via a route selected from the group consisting of a subcutaneous route, an  
intravenous route and an intramuscular route, among other routes. In a preferred  
25 embodiment, the methods of the present invention include administering at least one dose of  
a non-virulent, *recA* defective mutant of *Porphyromonas gingivalis*, wherein the dose is  
between about a  $1 \times 10^3$  and  $1 \times 10^7$  bacteria per kg of body weight of the mammal. More  
preferably, the dose is between about  $1 \times 10^5$  and  $1 \times 10^6$  bacteria per kg of body weight of the  
mammal.

## FIGURES

These and other features, aspects and advantages of the present invention will become better understood with regard to the following description, appended claims, and accompanying figures where:

5           Figures 1 and 2 show the results of Southern blot analyses of allelic exchange mutants of *P. gingivalis* to confirm the presence of the *ermF-ermAM* cassette in a predicted location;

          Figure 3 is a bar graph showing the results of an assay for arginine specific proteolytic activity of *P. gingivalis* FLL32, FLL33 and W83 in the presence or absence of L-cysteine;

10

          Figures 4 and 5 are bar graphs showing the results of an assay for the localization of arginine-specific proteolytic activity and for lysine-specific proteolytic activity, respectively, of *P. gingivalis* FLL32, FLL33 and W83 in the presence or absence of L-cysteine;

15           Figures 6 and 7 show the results of Northern blot analyses of *prpRI* and *prtP* protease genes, respectively, of *P. gingivalis* FLL32, FLL33 and W83;

          Figure 8 shows the results of an analysis by SDS-PAGE of the ability of *P. gingivalis* FLL32, FLL33 and W83 to degrade purified C3 complement protein; and

          Figure 9 is a graph showing the results of accumulation of C3 fragments on the bacterial surface of FLL32, FLL33 and W83.

20

## DESCRIPTION

          The present invention involves the discovery of a non-virulent mutant of *Porphyromonas gingivalis*. This mutant, designated FLL32, has been found to convey protection against the wild-type *Porphyromonas gingivalis* W83 in mammals when the mammal was immunized with the mutant strain FLL32. Further, FLL32 can be used as a host genetic background to determine the specific roles, interactions, relative importance and regulation of the potential virulence factors produced by wild-type *P. gingivalis*.

25

          All publications mentioned in this document are incorporated by reference in their entirety.

30           A deposit of *Porphyromonas gingivalis* mutant strain FLL32 has been made at the ATCC, Manassas, Virginia, US on April 8, 1998, under the accession number 202109.

This deposit shall be viably maintained, replacing it if it becomes non-viable, for a period of 30 years from the date of the deposit, or for 5 years from the last date of request for a sample of the deposit, whichever is longer, and made available to the public without restriction in accordance with the provisions of the law. The Commissioner of Patents and Trademarks, upon request, shall have access to the deposit.

In summary, the FLL32 strain was isolated during construction of a mutant *recA*<sup>-</sup> mutant of *P. gingivalis* W83 wild-type by allelic exchange mutagenesis. The FLL32 strain was *recA*<sup>-</sup> and lacked black pigmentation and  $\beta$ -hemolytic activity on blood agar. Further, the FLL32 strain was deficient in proteolytic activity and significantly more sensitive to UV irradiation than the wild-type W83 strain.

The FLL32 strain exhibited substantially reduced virulence when introduced into mammals and protected those animals immunized with that strain against subsequent infection by the wild-type strain W83. Further, in Western blot experiments of whole cell extracts, unique immunoreactive bands were found in FLL32 using sera from immunized animals. The FLL32 strain is the first nonvirulent *recA*<sup>-</sup> strain of *P. gingivalis* shown to protect mammals against subsequent infection by the wild-type *P. gingivalis*.

#### Isolation and Characterization of *P. gingivalis* FLL32 Strain

*Porphyromonas gingivalis* FLL32 was isolated and characterized as follows. First, the *recA* homolog gene was cloned from wild-type W83. Next, the *recA* homolog gene was sequenced. Then, an isogenic *recA*<sup>-</sup> mutant of *P. gingivalis* W83 designated FLL32 was constructed by allelic exchange mutagenesis and the presence of the defective *recA* DNA in the *P. gingivalis* FLL32 strain confirmed by Southern blot analyses.

Next, the phenotype and UV sensitivity of *P. gingivalis* FLL32 strain was determined, as well as its arginine and lysine specific proteolytic activity. Additionally, the amount of its mRNA transcript for the major protease genes was determined. Then, the amount of its C3 complement protein degradation was determined and the amount of C3 accumulation on the surface of the *P. gingivalis* FLL32 strain was determined. Finally, the virulence of the *P. gingivalis* FLL32 strain and protective effect of immunization by the FLL32 strain against subsequent challenge by the wild-type was examined.

#### (a) Cloning of the *recA* Homolog Gene from *P. gingivalis* W83

The *recA* homolog gene was cloned from *P. gingivalis* W83 as follows. First,

degenerate oligonucleotide primers (Dybvig, K., et al., "Degenerate oligonucleotide primers for enzymatic amplification of *recA* sequences from gram-positive bacteria and mycoplasmas." *J.Bacteriol.* 174, 2729-2732, 1992) were used in a polymerase chain reaction (PCR) to amplify a 320 bp fragment of the *recA* sequence of *P. gingivalis* W83.

- 5 This PCR fragment was <sup>32</sup>P-labeled and used to screen a λ DASH recombinant phage bank *P. gingivalis* W83 for the presence of hybridizing clones. Ten of 1x10<sup>3</sup> phage clone plaques (1.0%) hybridized with the probe.

The hybridizing phage plaques were then amplified and absorbed onto maltose-grown *E. coli* cells. DNA from the phage clones was isolated using the Promega  
10 Lambda Wizard DNA Purification system (Promega, Corporation, Madison, WI). *NotI*-*Bam*HI cleavage of purified DNA from two of the recombinants, designated L2 and L10, revealed that the phage clones had different restriction fragment patterns. L2 contained an 8.0 kb and a 6.5 kb fragment that were missing in L10, while L10 contained an 11 kb, a 5.8 kb and a 0.3 kb fragment that were missing in L2. Both L2 and L10 contained a similar 2.1  
15 kb fragment. These data indicated that the L2 and L10 clones were independent clones and not siblings from a single cloning event.

The L10 clone was chosen for further study because it had the smaller fragment insert. Southern blot hybridization using the <sup>32</sup>P-labeled 0.3kb PCR fragment of the *recA* gene from the chromosome of W83 was used as a probe to identify the hybridizing  
20 fragment. The plasmid pUC19 was used to subclone a 2.1 kb hybridizing *Bam*HI fragment from L10. This clone was designated pFLL26.

#### (b) Nucleotide Sequencing of the *recA* Homolog Gene

Both strands of the 2.1 kb hybridizing *Bam*HI fragment from the L10 clone carried on pFLL26 were sequenced and one 1.02 kb open reading frame corresponding to a  
25 36 kDa protein was detected, GenBank Accession Number U70054 (Fletcher et al., 1997). There was a start codon at base position 774. A purine-rich sequence found in *E. coli* ribosome binding sites was also seen three bases upstream from the initiation site. Sequences resembling prokaryotic -10 and -35 promoter regions were detected at base positions 749 and 729 respectively. The calculated G+C ratio for the *recA* homolog gene was 50% which is  
30 close to the ratio of 46 to 48% previously reported for genomic *P. gingivalis* DNA (Shah and Collins, 1988).

A comparison of the amino acid sequence of this gene with the National Center for Biotechnology Information genetic sequence databank revealed a similarity of approximately 90, 86 and 82 percent to the RecA proteins from *Bacteroides fragilis*, *Prevotella ruminicola*, GenBank Accession Number U21227, and *Mycobacterium smegmatis*, GenBank Accession Number X99208, respectively. (Goodman and Woods, Molecular Analysis of the *Bacteroides fragilis recA* Gene, Gene 94, pp. 77-82, 1990) Further, regions between amino acids 68 to 81 and 266 to 288 revealed conserved ATP binding domains.

(c) Construction of a *recA* Mutant in *P. gingivalis* W83

An isogenic *recA* mutant of *P. gingivalis* W83 was constructed by allelic exchange mutagenesis as follows. The nucleotide sequence of the cloned *recA* fragment revealed a unique *HincII* restriction site at bp 435 of the open reading frame (Fletcher, H.M. et al., "Nucleotide sequence of *Porphyromonas gingivalis* W83 *recA* homolog and construction of a *recA*-deficient mutant." *Infect.Immun.* 65, 4592-4597, 1997). To utilize this site, a 1.8 kb *EcoRI-PstI* fragment containing the intact *recA* gene was subcloned into *EcoRI-PstI* cleaved pUC19. The resulting plasmid, pFLL23, was digested with *HincII* and ligated with the 2.1 kb *ermF-ermAM* cassette from pVA2298 to produce recombinant plasmid designated pFLL24. (See Fletcher, H.M., Schenkein, H.A., Morgan, R.M., Bailey, K.A., Berry, C.R., and Macrina, F.L. (1995). Virulence of a mutant of *Porphyromonas gingivalis* W83 that is defective in the *prtH* gene. *Infect.Immun.* 63, 1521-1528).

Then, the recombinant plasmid pFLL24 was used as donor DNA in electroporation of *P. gingivalis* W83. Since the pFLL24 plasmid was unable to replicate in *P. gingivalis*, Clindamycin resistant (C<sup>c</sup>) transformants could only arise as a result of an integration into the wild-type gene on the chromosome. Two double crossover events were predicted between the regions flanking the *erm* marker and the wild-type *recA* gene on the chromosome that would result in a replacement of a segment of the wild-type gene with a fragment conferring clindamycin resistance.

Following electroporation and plating on selective medium, 15 C<sup>c</sup> colonies were detected after a 7 day incubation period. These colonies were replica plated onto selective medium and exposed to UV light to determine their sensitivity. Four UV sensitive colonies, designated FLL32, FLL33, FLL34 and FLL35, were chosen from the unexposed plate for further study.



To confirm the presence of the *ermF-ermAM* cassette in the predicted location, that is interrupting the *recA* DNA, Southern blot analyses were performed on the total cellular DNA from *P. gingivalis* wild-type W83, as a control, and from the Cc<sup>r</sup> transformants FLL32, FLL33, FLL34 and FLL35. Their DNA was cleaved with *Bam*HI, electrophoresed through 0.7% agarose, bidirectionally transferred to nitrocellulose and probed with <sup>32</sup>P labeled pFLL23 and pVA2198. If the DNA was digested with *Bam*HI, a predicted 2.1 kb fragment would be seen. If the DNA was not digested with *Bam*HI, a predicted 4.2 kb fragment would be seen. Since the *ermF-ermAM* cassette is missing a *Bam*HI site, any of the four Cc<sup>r</sup> transformants with the *ermF-ermAM* cassette interrupting the *recA* DNA sequence should have shown a 4.2 kb fragment but not a 2.1 kb fragment.

Referring now to Figures 1 and 2, there are shown the results of the Southern blot analyses of allelic exchange mutants of *P. gingivalis* to confirm the presence of the *ermF-ermAM* cassette in the predicted location. As can be seen in Figure 1, the predicted 2.1 kb fragment was seen in the wild-type *P. gingivalis* W83, lane A, using the <sup>32</sup>P-labeled pFLL23 that carries the *P. gingivalis* *recA* homolog as a probe, indicated the presence of the *recA* DNA. In contrast, a 4.2 kb fragment was present in each of the four Cc<sup>r</sup> mutants of W83, lanes B-E, FLL32, FLL33, FLL34 and FLL35, respectively, and indicated the presence of the *recA* DNA sequence interrupted by the *ermF-ermAM* cassette.

As can be seen in Figure 2, using pVA2198, which carried the *ermF-ermAM* cassette as a probe, revealed an identical 4.2 kb hybridizing fragment present in the four Cc<sup>r</sup> mutants, lanes B-E, FLL32, FLL33, FLL34 and FLL35, respectively, but not in the wild-type W83, lane A, indicating the presence of the *ermF-ermAM* cassette only in the transformants. pUC19 vector sequences used as a control did not hybridize with W83 or any of the four Cc<sup>r</sup> mutants, FLL32, FLL33, FLL34 and FLL35 (data not shown). These data indicated that recombination had occurred in the four Cc<sup>r</sup> mutants, FLL32, FLL33, FLL34 and FLL35, resulting in the wild-type *recA* gene being interrupted by the *ermF-ermAM* cassette in FLL32, FLL33, FLL34 and FLL35.

#### (d) Phenotypic Characterization of *P. gingivalis* W83 *recA* Mutants

The phenotype of *P. gingivalis* W83 *recA* mutants were initially characterized as follows. The *recA* mutants, FLL32, FLL33, FLL34 and FLL35, were plated on Brucella blood agar plates (Anaerobic Systems, Inc., San Jose, CA) to determine if any pleiotropic

effects were associated with inactivation of the *recA* gene. Two classes of mutants were observed. The first class, a single colony FLL32, was unpigmented and displayed significantly less  $\beta$ -hemolysis than the wild-type W83. The second class contained three strains, FLL33, FLL34 and FLL35, all of which displayed similar  $\beta$ -hemolytic activity and black pigmentation as the wild-type W83. FLL32 and FLL33 were chosen for further study as representatives of their respective classes. A generation time of 3 hours was determined for W83 and of 3.5- 4 hours for both FLL32 and FLL33.

**(e) Determination of the UV Sensitivity of *P. gingivalis* W83 *recA* Mutants**

To confirm the loss of activity of the *P. gingivalis* RecA protein, the relative sensitivity of the wild-type and *recA*<sup>-</sup> strains to UV irradiation was determined as follows. Wild-type W83 and *recA*<sup>-</sup> mutants FLL32 and FLL33 were exposed to 1000  $\mu$ joules of UV irradiation. There was an 80% survival of the wild-type W83 strain in contrast to the 18% survival for FLL32 and FLL33. When wild-type W83 and mutants FLL32 and FLL33 were exposed to 2000  $\mu$ joules of UV irradiation, there was 40% survival of the wild-type W83 cells compared to 0% survival for the *recA*<sup>-</sup> mutants FLL32 and FLL33. These data indicated that the *recA* gene of *P. gingivalis* W83 plays an important role in repairing DNA damage caused by UV irradiation and that both FLL32 and FLL33 were *recA* defective.

**(f) Determination of the Arginine and Lysine Specific Proteolytic Activity of FLL32, FLL33 and W83**

The arginine specific proteolytic activity of *P. gingivalis* W83 *recA* mutants was determined by assaying whole cell preparations from each of the three strains of *P. gingivalis*, FLL32, FLL33 and W83 for proteolytic activity using *N*- $\alpha$ -benzoyl-DL-arginine *p*-nitroanilide (BAPNA). Each strain of *P. gingivalis* was grown for 48 hours to late log phase (OD<sub>600</sub> of 1.2) in 500 ml BHI broth supplemented with hemin and vitamin K. The cells were then washed in PBS (pH 7.3) and resuspended to an OD<sub>600</sub> of 0.3. 50 $\mu$ l of the cell samples were incubated for 10 min at 37°C in 50mM Tris-HCl (pH 7.0), and 1mM  $\alpha$ -N-benzoyl-arginine-DL-*p*-nitroanilide (BAPNA) in the presence or absence of 0.5 mM L-cysteine. The control contained buffer alone. Hydrolysis of BAPNA was monitored by the change of absorbance at 410 nm.

Referring now to Figure 3, there is shown a bar graph of the assay results. As can be seen, the wild-type W83 (-Cys) showed more proteolytic activity than FLL33 (-Cys),

while FLL32 (-Cys) did not show significantly more proteolytic activity than the control. The activity from all three strains was enhanced in the presence of cysteine (+Cys) but the relative rates of proteolytic activity remained the same. The reduction of proteolytic activity seen in FLL33 compared to W83 could be related to the longer generation time for the *recA*<sup>-</sup> strains compared to the wild-type W83.

Localization of the arginine-specific proteolytic activity and for lysine-specific proteolytic activity in the *recA*<sup>-</sup> strains was determined as follows. First, extracellular proteolytic activity was tested. Ammonium sulfate was added to 500 ml of culture supernatant from cells grown to late log phase (OD<sub>600</sub> of 1.2) to 100% saturation. The precipitate was resuspended in 3 ml of PBS (pH 7.3), dialyzed against the same buffer, and then stored at -20°C.

Referring now to Figures 4 and 5, there are shown bar graphs showing the results of an assay for the localization of arginine-specific proteolytic activity and for lysine-specific proteolytic activity. As can be seen, the FLL33 showed more extracellular arginine-specific proteolytic activity and more lysine-specific proteolytic activity than the wild-type W83 (-Cys). FLL32 did not show significantly more arginine-specific proteolytic activity or lysine-specific proteolytic activity than the control. Further, the extracellular arginine-specific proteolytic activity of both W83 and FLL33, but not FLL32, was enhanced in the presence of cysteine (+Cys).

Next, intracellular proteolytic activity was tested. The cells from the above experiment were washed in PBS (pH 7.4), and then resuspended in the same buffer to a final volume of 10 ml. 1 ml aliquots were transferred to microcentrifuge tubes containing 0.5 volume of 0.1 mm zirconium beads (Biospec Products, Inc. Bartlesville, OK), then lysed in a Mini-Bead Beater homogenizer (Biospec Products) for 3 min. Beads and cellular debris were removed by centrifugation at 12,000 x g for 5 min to obtain a clear lysate. Using 100 µg of protein per assay, similar intracellular arginine- and lysine-specific proteolytic activities were observed for the W83 and FLL33 strains, but there was no significant intracellular arginine- or lysine-specific proteolytic activities for FLL32 (data not shown).

**(g) Comparison of the Presence and Amount of mRNA Transcript for the Major Protease Genes in FLL32, FLL33 and W83**

The loss of proteolytic activity in strain FLL32 could have resulted either from a lack of transcription or translation of the gene, or from a lack of post-translational  
5 activation of the precursor product. In order to determine the cause of the loss of proteolytic activity in FLL32, the presence and amount of mRNA transcript for the major protease genes in FLL32, FLL33 and W83 was determined as follows.

First, total RNA was isolated using the Qiagen RNeasy Kit (Qiagen, Valencia, CA) from the wild-type W83 strain and from the FLL32 and FLL33 mutants grown to mid-  
10 log phase ( $OD_{600}$  of 0.2). Unique oligonucleotide primers for *prtP* (as disclosed in Barkocy-Gallagher, G.A. et al., "Analysis of the *prtP* gene encoding porphypain, a cysteine proteinase of *Porphyromonas gingivalis*." *J.Bacteriol.* 178, 2734-2741, 1996), *prpRI* (Aduse Opoku, J. et al., "Characterization, genetic analysis, and expression of a protease antigen (PrpRI) of *Porphyromonas gingivalis* W50." *Infect.Immun.* 63, 4744-4754, 1995) and *prtRII*  
15 were used in RT-PCR to amplify a 1 kb region of the transcripts. Amplified products of the predicted 1 kb size were observed for all three protease gene transcript in all three strains (data not shown). Further, there were no observed differences seen in the concentration of the amplified product between the genes of the three strains. Therefore, both FLL32 and FLL33 strains produce the same mRNA transcripts for the major protease genes in the same  
20 amounts as the wild-type W83. As a control, *recA* intragenic primers amplified the expected 0.72 kb region only in the wild-type W83 strain.

The presence of the mRNA transcripts for the *prpRI* and *prtP* proteases in all three *P. gingivalis* strains were further confirmed in Northern blot analysis using an amplified intragenic region of each gene as a probe. Total RNA was extracted from each of  
25 the W83, FLL32 and FLL33 strains grown to mid-log phase ( $OD_{600}$  of 0.2) using the Qiagen RNeasy midi kit (available from Qiagen, Valencia, CA, according to the manufacturer's instructions). RNA samples of 1  $\mu$ g were then separated by agarose gel electrophoresis and transferred to nitrocellulose filter according to the method of Sambrook et al. (Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989). *Molecular Cloning: A Laboratory Manual*. Second  
30 edition. (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press)).

Referring now to Figures 6 and 7, there are shown the results of the Northern blot analysis of *prpRI* and *prpP* protease genes from the three strains of *P. gingivalis* W83, FLL33 and FLL32. Figure 6 shows the results using a <sup>32</sup>P-labeled specific intragenic region of *prpRI* as the probe. Figure 7 shows the results using a <sup>32</sup>P-labeled specific intragenic region of *prpP* as the probe. The size of the transcripts in kb are given in the left margins. Lane A shows the results for the W83 wild-type strain, lane B shows the results for the FLL32 mutant strain and lane C shows the results for the FLL33 mutant strain.

As can be seen in Figure 6, the *prpRI* probe hybridized to 6.3 and 4.2 kb transcripts. As can be seen in Figure 7, the *prpP* probe hybridized to 6.6, 4.3 and 3.2 kb transcripts. The 6.3 and 6.6 kb transcripts for the *prpRI* and *prpP* genes, Figures 6 and 7 respectively, are consistent with the known size of those genes transcripts. The presence of the smaller transcripts could be degraded product or could be transcripts that share regions of homology with the protease genes. These results confirm the presence of the mRNA transcripts of the *prpRI* and *prpP* protease genes in all three strains of *P. gingivalis*, W83, FLL32 and FLL33.

#### (h) Determination of the C3 Complement Protein Degradation of FLL32, FLL33 and W83

The ability of *P. gingivalis* FLL32, FLL33 and W83 to degrade purified C3 complement protein was determined as follows. 1 mg/ml of C3 was incubated with increasing dilutions of each strain at 37°C for 30 minutes and the supernatant were analysed by SDS-PAGE with 10% separation gels and stained with comassie. The results are shown in Figure 8 using C3 alone as a control (lane 1), 10<sup>9</sup> W83 cells/ml (lane 2), 5x10<sup>8</sup> W83 cells/ml (lane 3), 10<sup>8</sup> W83 cells/ml (lane 4), 10<sup>9</sup> FLL32 cells/ml (lane 5), 5x10<sup>8</sup> FLL32 cells/ml (lane 6), 10<sup>8</sup> FLL32 cells/ml (lane 7), 10<sup>9</sup> FLL33 cells/ml (lane 8), 5x10<sup>8</sup> FLL33 cells/ml (lane 9) and 10<sup>8</sup> FLL33 cells/ml (lane 10).

As can be seen, the highest concentration of W83 tested (lane 2) completely degraded the  $\alpha$ -chain of C3 with generation of C3b and some lower molecular mass fragments similar to C3c and C3d. The lowest bacterial concentration of W83 tested (lane 4) partially degraded the  $\alpha$ -chain, causing both  $\alpha$  and  $\alpha'$ -chains to be visible. Similar results were observed for FLL33 (lanes 8-10). In contrast, the highest concentration of FLL32 (lane 6) only minimally degraded C3 to C3b and lower molecular mass cleavage fragments. There

was no degradation of C3 at the lowest bacterial concentration tested for FLL32. Thus, FLL32 is less capable of degrading C3 than either the wild-type W83 or FLL33.

**(i) Assessment of C3 Accumulation on FLL32, FLL33 and W83**

Opsonization of *P. gingivalis* strains W83, FLL32 and FLL33 was assessed for the accumulation of C3 fragments on the bacterial surface as follows.  $5 \times 10^8$  cells/ml of each strain was incubated in pooled human serum that was diluted 1:3 with Veronal-buffered saline (0.01 M Veronal buffer, pH 7.5, containing 0.13 M NaCl) and that contained  $2 \mu\text{g/ml}$   $^{125}\text{I}$ -C3 for 35 minutes. The incubated bacterial samples were then washed and assessed for bound  $^{125}\text{I}$ -C3 fragments by scintillation counting. Referring now to Figure 9, it can be seen that W83 failed to accumulate substantial amounts of C3 by the end of the incubation period. In contrast, FLL33 accumulated  $3 \times 10^4$  molecules/bacterium and FLL32 accumulated  $6 \times 10^4$  molecules/bacterium of  $^{125}\text{I}$ -C3 fragments. Taken together, these results suggest that FLL32 has an increased capacity to be opsonized with C3 fragments compared to both W83 and FLL33.

**EXAMPLE I**

**Comparison of the Virulence Between FLL32, FLL33 and W83 in a Mammal**

A first comparison of the virulence between wild-type W83, mutant strain FLL32 and mutant strain FLL33 *Porphyromonas gingivalis* in a mammal was made as follows. Sixteen female Balb/c mice (8-10 weeks old, Harlan Sprague Dawley Inc., Indianapolis IN) were divided into three groups, five in Group I, five in Group II and six in Group III. Each animal received a single challenge dose of  $1 \times 10^{10}$  bacteria *P. gingivalis* W83 (Group I), FLL33 (Group II) or FLL32 (Group III) by subcutaneous, dorsal surface injection, a dosage of approximately  $2 \times 10^4$  bacterial per kg body weight.

At 24 hours post-challenge, two of the five animals in Group I and one of the five animals in the Group II had died and the remaining animals in both Groups I and II appeared cachectic and hunched with ruffled hair. Although the animals did not display lesions at the dorsal surface site of injection (primary site), all had developed spreading, ulcerative abdominal skin lesions (secondary site). All of the remaining animals in the Group I and three of the four remaining animals in the Group II died by 48 hours post-challenge. The fifth animal in the Group II died by the fourth day post-challenge.

In contrast, all six of the animals in Group III challenged with FLL32 survived the 14 day post-challenge observation period. None of the animals in Group III had any observable negative effects from the challenge.

5 The data from these challenges were analyzed using Fisher's Exact Test. The analysis found no difference in the virulence between W83 and FLL33 ( $p=1.000$ ). However, the FLL32 strain had a statistical difference in virulence when compared to FLL33 ( $p=0.002$ ) and W83 ( $p=0.002$ ).

10 A second comparison of the virulence between wild-type W83, mutant strain FLL33 and mutant strain FLL32 *Porphyromonas gingivalis* in a mammal was made as follows. Seventeen mice Balb/c mice (8-10 weeks old, Harlan Sprague Dawley Inc., Indianapolis IN) were divided into three groups, five in Group IV, six in Group V and six in Group VI. Each animal received a single challenge dose of  $5 \times 10^9$  bacteria *P. gingivalis* W83 (Group IV), FLL33 (Group V) or FLL32 (Group VI) by dorsal subcutaneous surface injection.

15 At 24 hours post-challenge, one of five animals in Group IV had died and the remaining four had developed ulcerated abdominal skin lesions. By 48 hours post-challenge, three of the remaining animals in Group IV had died. The lesions in the surviving fifth animal were resolving at day 14 post-challenge.

20 At 24 hours post-challenge, one of six animals in Group V had died and the remaining five had developed ulcerated abdominal lesions. By 48 hours post-challenge, three of the five remaining animals in Group V had died. One additional animal died by day 5 post-challenge. The lesions in the surviving sixth animal were resolving at day 14 post-challenge.

25 In contrast, all six of the animals in Group VI challenged with FLL32 survived the 14 day post-challenge observation period. None of the animals in Group VI had any observable negative effects from the challenge.

30 The results of these challenges were analyzed using Fisher's Exact Test. The analysis found no difference in the virulence between W83 and FLL33 ( $p=0.727$ ). However, the FLL32 strain had a statistical difference in virulence when compared to FLL33 ( $p=0.008$ ) and W83 ( $p=0.015$ ).

As can be appreciated from this Example, the inactivation of the *recA* gene in *P. gingivalis* FLL33 did not significantly affect the virulence of *P. gingivalis*. However, the mutation in the FLL32 strain significantly affected the virulence of *P. gingivalis*.

## EXAMPLE II

### 5           **Demonstration of the Protective Effect of Immunization with FLL32 Against                   Subsequent Challenge with Wild-Type W83 *P. gingivalis***

The protective effect of immunization of a mammal with FLL32 against subsequent challenge with wild-type W83 *P. gingivalis* was demonstrated as follows. Sixteen female Balb/c mice (8-10 weeks old, Harlan Sprague Dawley Inc., Indianapolis IN) were  
10 subcutaneously immunized once per week for 3 weeks with  $1 \times 10^{10}$  bacteria of the mutant strain FLL32, a dosage of  $5 \times 10^5$  bacteria per kg of body weight. Ten additional female Balb/c mice (8-10 weeks old, Harlan Sprague Dawley Inc., Indianapolis IN) were subcutaneously immunized once per week for 3 weeks with sterile phosphate-buffered saline (PBS) as a control. All of the animals immunized with FLL32 and five of the ten animals  
15 immunized with PBS were then challenged 2 weeks after the final immunization by subcutaneous injection of a *P. gingivalis* W83 wild-type suspension containing  $1 \times 10^{10}$  cells, a dosage of  $5 \times 10^5$  bacteria per kg of body weight. The remaining five animals immunized with PBS were challenged 2 weeks after the final immunization by subcutaneous injection of PBS as a control.

20           By 24 hours post-challenge, one of the five control animals immunized with PBS and challenged with *P. gingivalis* W83 died and the other four animals had developed spreading infections with secondary site abdominal skin ulcerations and, in some, primary site ulcerations around the base of the tail. All of these mice exhibited severe cachexia with ruffled hair, hunched bodies and weight loss; and all of these five control animals died by  
25 four days post-challenge.

In contrast, eight of sixteen animals immunized with *P. gingivalis* FLL32 and challenged with *P. gingivalis* W83 displayed only minor secondary skin site abdominal infections by 24 hours post-challenge but all recovered and were alive at the end of the test period. Of the remaining eight animals immunized with *P. gingivalis* FLL32 and challenged  
30 with *P. gingivalis* W83, five had severe cachexia and died by three days post-challenge, two had moderate cachexia and developed secondary ulcerating abdominal lesions which began to



heal at day 5 post-challenge and were alive at the end of the fourteen day experiment period, and the last animal developed a secondary lesion which healed but then developed an additional secondary lesion and died at day 7 post-challenge.

All of the five animals immunized with PBS and challenged with PBS  
5 appeared normal throughout the fourteen day experiment period.

The results of these challenges were analyzed using Fisher's Exact Test. The analysis found that immunization with the FLL32 strain protected the animals from a wild-type challenge ( $p=0.148$ ), while those animals that were immunized with sterile phosphate-buffered saline were not protected ( $p=0.023$ ).

10 At the end of the fourteen day experiment period, the ten surviving animals from the group originally immunized with FLL32 and then challenged with W83, and the five animals immunized with PBS and challenged with PBS were sacrificed and their sera were isolated to ascertain the presence of anti-FLL32 antibodies. A 1:1000 dilution of the sera was tested by Western blot analysis for cross-reactivity to whole cell lysates of *P. gingivalis* W83, FLL32 and FLL33.

15 Animals immunized with FLL32 were positive for antibodies to each of the *P. gingivalis* whole cell lysates (data not shown). Immunoreactive bands with molecular mass of 96, 82, 74, 55.2, 49.6, 38, 37, and 35 kDa were observed in the Western blot analyses of each of the whole cell lysates of FLL32, FLL33 and W83. Immunoreactive bands with  
20 molecular mass of 44 and 40 kDa were present in the Western blot analyses of each of the whole cell lysates of FLL33 and W83 but were absent from the Western blot analysis of the whole cell lysates of FLL32. Further, immunoreactive bands with molecular mass of 185, 170, 125, 71, 68, 63 and 47 kDa were present in the Western blot analyses of whole cell  
25 lysates of FLL32 but were absent in the Western blot analysis of each of the whole cell lysates of FLL33 and the W83 strain.

In contrast, sera from animals immunized with PBS and challenged with PBS were negative for antibodies to each of the *P. gingivalis* whole cell lysates.

### EXAMPLE III

#### Method of Decreasing the Growth Rate or Reproduction Rate

#### Of *Porphyromonas gingivalis* in a Mammal

30 According to one embodiment of the present invention, there is provided a

method of decreasing the growth rate or reproduction rate of *Porphyromonas gingivalis* in a mammal, such as a human. The method comprises the step of administering to the mammal at least one dose of a non-virulent, *recA*<sup>-</sup> mutant of *Porphyromonas gingivalis*, such as FLL32. The dose can be administered, for example, by subcutaneous, intramuscular or intravenous injection. In a preferred embodiment, the dosage is between about  $1 \times 10^3$  and  $1 \times 10^7$  bacteria per kg of body weight. In a particularly preferred embodiment, the dosage is between about  $1 \times 10^5$  and  $1 \times 10^6$  bacteria per kg of body weight.

Among the uses of decreasing the growth rate or reproduction rate of *Porphyromonas gingivalis* in a mammal, such as a human, is the prevention or treatment of periodontitis, or other diseases or conditions caused in whole or in part by *Porphyromonas gingivalis*, such as aspiration pneumonia and necrotizing pneumonia, abscesses in brain, genitourinary tract and lung, and mediastinitis

Although the present invention has been discussed in considerable detail with reference to certain preferred embodiments, other embodiments are possible. Therefore, the spirit and scope of the appended claims should not be limited to the description of preferred embodiments contained herein.

**I CLAIM:**

1. A non-virulent, *recA* defective mutant of *Porphyromonas gingivalis*.
2. The *Porphyromonas gingivalis* strain which is deposited at ATCC under accession number 202109.
- 5        3. A pharmaceutical preparation comprising the mutant of *Porphyromonas gingivalis* according to claim 1.
4. A pharmaceutical preparation comprising the mutant of *Porphyromonas gingivalis* according to claim 2.
- 10       5. A method of decreasing the growth rate or reproduction rate of *Porphyromonas gingivalis* in a mammal, the method comprising the step of administering to the mammal at least one dose of a non-virulent, *recA* defective mutant of *Porphyromonas gingivalis*.
6. The method of claim 5, wherein the mammal is a human.
7. The method of claim 5, wherein the step of administering includes administering at least one dose of the mutant of *Porphyromonas gingivalis* according to claim 2 to the  
15       mammal.
8. The method of claim 7, wherein the mammal is a human.
9. A method of decreasing the growth rate or reproduction rate of *Porphyromonas gingivalis* in a mammal, the method comprising the step of administering to the mammal at least one dose of *Porphyromonas gingivalis* according to claim 2 to the mammal.
- 20       10. A method of preventing or treating a *Porphyromonas gingivalis* infection such as periodontitis in a mammal, the method comprising the step of administering to the mammal at least one dose of a non-virulent, *recA* defective mutant of *Porphyromonas gingivalis*.
11. The method of claim 10, wherein the mammal is a human.
12. A method of preventing or treating a *Porphyromonas gingivalis* infection such as  
25       periodontitis in a mammal, wherein the step of administering includes administering at least one dose of the mutant of *Porphyromonas gingivalis* according to claim 2 to the mammal.
13. The method of claim 12, wherein the mammal is a human.
14. The method of claim 5, wherein the step of administering comprises injecting the  
30       mutant with the at least one dose of a non-virulent, *recA* defective mutant of *Porphyromonas gingivalis* via a route selected from the group consisting of a subcutaneous route, an intravenous route and an intramuscular route.

15. The method of claim 5, wherein the step of administering comprises injecting the mutant with the at least one dose of a non-virulent, *recA* defective mutant of *Porphyromonas gingivalis*, wherein the dose is between about a  $1 \times 10^3$  and  $1 \times 10^7$  bacteria per kg of body weight.

5        16. The method of claim 5, wherein the step of administering comprises injecting the mutant with the at least one dose of a non-virulent, *recA* defective mutant of *Porphyromonas gingivalis*, wherein the dose is between about  $1 \times 10^5$  and  $1 \times 10^6$  bacteria per kg of body weight.

10       17. The method of claim 10, wherein the step of administering comprises injecting the mutant with the at least one dose of a non-virulent, *recA* defective mutant of *Porphyromonas gingivalis* via a route selected from the group consisting of a subcutaneous route, an intravenous route and an intramuscular route.

15       18. The method of claim 10, wherein the step of administering comprises injecting the mutant with the at least one dose of a non-virulent, *recA* defective mutant of *Porphyromonas gingivalis*, wherein the dose is between about a  $1 \times 10^3$  and  $1 \times 10^7$  bacteria per kg of body weight.

20       19. The method of claim 10, wherein the step of administering comprises injecting the mutant with the at least one dose of a non-virulent, *recA* defective mutant of *Porphyromonas gingivalis*, wherein the dose is between about  $1 \times 10^5$  and  $1 \times 10^6$  bacteria per kg of body weight.

1/7

FIG. 2







FIG. 1




2/7



3/7



4/7





5/7

FIG. 7





FIG. 6



6/7





FIG. 8

7 / 7



## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>2</u> , line <u>5</u> through <u>7</u>	
B. IDENTIFICATION OF DEPOSIT	
Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit April 8, 1998	Accession Number 202109
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application <b>RO/US 11 AUG 1999</b> Authorized officer <b>Yolanda Harrod</b> <b>PCT/Internat'l Appl Processing Div.</b> <b>(703) 305-3670</b>	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on: Authorized officer
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/18197

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 39/02, 39/00; A10N 63/00

US CL :424/234.1, 184.1, 93., 93.4

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/234.1, 184.1, 93., 93.4

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DIALOG, MEDLINE, EMBASE, WEST, BIOSIS

Porphyromonas(2w)gingivalis, recA; Inventors' name search

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	FLETCHER et al. Cloning and sequencing of a recA-like gene from Porphyromonas gingivalis W83. J. Dent. Res. November 1997, Vol. 76, IADR abstract 1104, page 151, see entire abstract.	1-4 ----- 5-19
X --- Y	FLETCHER et al. Nucleotide sequence of the Porphyromonas gingivalis W83 recA homolog and construction of a recA-deficient mutant. Infect. Immun. November 1997, Vol. 65, No. 11, pages 4592-4597, see entire document.	1-4 ----- 5-19
X --- Y	FLETCHER, H. M. Virulence of recA-defective mutants of Porphyromonas gingivalis W83. In: Abstracts of the 97th General Meeting of the American Society for Microbiology, 04-08 May 1997, Miami Beach, Florida, abstract B-424, page 101, see entire abstract.	1-4 ----- 5-19



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

04 NOVEMBER 1999

Date of mailing of the international search report

07 DEC 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

S. DEVI

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/18197

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/18197

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claims 1-4, 5-9 and 14-16, drawn to a non-virulent, *recA* defective mutant of *Porphyromonas gingivalis*, a pharmaceutical preparation comprising the same, a strain of *Porphyromonas gingivalis* and a method of decreasing the growth rate or reproduction of *Porphyromonas gingivalis* in a mammal.

Group II, claims 10-13, drawn to a method of preventing or treating a *Porphyromonas gingivalis* infection.

The inventions listed as Groups I and II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The claims of Group I encompass a bacterium product, a mutant bacterium and a composition comprising the mutant and the first method of using the product, which is a permitted combination of categories under PCT Rule 13.2. The claims of Group II are drawn to a second method of use of the product. There is no special unifying feature connecting Group I and Group II, because the method of preventing or treating does not require the bacterium of claim 2.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**